DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,788 INR | -1.52% |
|
-1.31% | -0.18% |
| May. 31 | Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading | MT |
| May. 30 | India's pharma export sales to grow faster this year, trade body says | RE |
| Sales 2024 | 280B 3.36B | Sales 2025 * | 300B 3.6B | Capitalization | 964B 11.55B |
|---|---|---|---|---|---|
| Net income 2024 | 55.78B 669M | Net income 2025 * | 54.89B 658M | EV / Sales 2024 | 3.43 x |
| Net cash position 2024 | 64.59B 774M | Net cash position 2025 * | 88.77B 1.06B | EV / Sales 2025 * | 2.92 x |
| P/E ratio 2024 |
18.4
x | P/E ratio 2025 * |
17.4
x | Employees | 25,863 |
| Yield 2024 |
0.65% | Yield 2025 * |
0.78% | Free-Float | 70.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -1.52% | ||
| 1 week | -1.31% | ||
| 1 month | -6.73% | ||
| 3 months | -9.86% | ||
| 6 months | -0.00% | ||
| Current year | -0.18% |
1 week
5 757.45
6 015.00
1 month
5 710.506 420.00
Current year
5 523.456 505.50
1 year
4 531.506 505.50
3 years
3 655.006 505.50
5 years
2 352.006 505.50
10 years
1 888.006 505.50
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.02% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 5,788 | -1.52% | 11,107 |
| 24-05-30 | 5,877 | -2.05% | 28,799 |
| 24-05-29 | 6,000 | +0.74% | 4,215 |
| 24-05-28 | 5,956 | +1.21% | 23,164 |
| 24-05-27 | 5,884 | +0.34% | 8,187 |
Delayed Quote Bombay S.E., May 31, 2024 at 06:00 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-06-03
- Investor Meeting - Bank of America
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
5,788
INR
Average target price
6,110
INR
Spread / Average Target
+5.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.18% | 11.55B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- DRREDDY Stock
